Annual Shareholders Equity:
$185.44M-$85.90M(-31.66%)Summary
- As of today, ARWR annual stockholders equity is $185.44 million, with the most recent change of -$85.90 million (-31.66%) on September 30, 2024.
- During the last 3 years, ARWR annual shareholders equity has fallen by -$223.38 million (-54.64%).
- ARWR annual shareholders equity is now -59.84% below its all-time high of $461.78 million, reached on September 30, 2020.
Performance
ARWR Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Shareholders Equity:
$522.31M-$161.01M(-23.56%)Summary
- As of today, ARWR quarterly stockholders equity is $522.31 million, with the most recent change of -$161.01 million (-23.56%) on June 30, 2025.
- Over the past year, ARWR quarterly shareholders equity has increased by +$191.77 million (+58.01%).
- ARWR quarterly shareholders equity is now -23.56% below its all-time high of $683.32 million, reached on March 31, 2025.
Performance
ARWR Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
ARWR Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | -31.7% | +58.0% |
| 3Y3 Years | -54.6% | +15.1% |
| 5Y5 Years | -24.2% | +5.9% |
ARWR Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | -53.5% | at low | -23.6% | +893.2% |
| 5Y | 5-Year | -59.8% | at low | -23.6% | +893.2% |
| All-Time | All-Time | -59.8% | +7157.3% | -23.6% | >+9999.0% |
ARWR Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $522.31M(-23.6%) |
| Mar 2025 | - | $683.32M(+1199.4%) |
| Dec 2024 | - | $52.59M(-71.6%) |
| Sep 2024 | $185.44M(-31.7%) | $185.44M(-43.9%) |
| Jun 2024 | - | $330.55M(-31.7%) |
| Mar 2024 | - | $483.79M(+201.6%) |
| Dec 2023 | - | $160.41M(-40.9%) |
| Sep 2023 | $271.34M(-31.9%) | $271.34M(-25.6%) |
| Jun 2023 | - | $364.83M(-18.3%) |
| Mar 2023 | - | $446.77M(+18.5%) |
| Dec 2022 | - | $377.04M(-5.4%) |
| Sep 2022 | $398.52M(-2.5%) | $398.52M(-12.2%) |
| Jun 2022 | - | $453.93M(+0.4%) |
| Mar 2022 | - | $452.27M(+21.4%) |
| Dec 2021 | - | $372.56M(-8.9%) |
| Sep 2021 | $408.82M(-11.5%) | $408.82M(-6.4%) |
| Jun 2021 | - | $436.89M(-1.9%) |
| Mar 2021 | - | $445.55M(-2.0%) |
| Dec 2020 | - | $454.47M(-1.6%) |
| Sep 2020 | $461.78M(+88.8%) | $461.78M(-6.4%) |
| Jun 2020 | - | $493.14M(-0.2%) |
| Mar 2020 | - | $494.12M(-1.2%) |
| Dec 2019 | - | $500.08M(+104.5%) |
| Sep 2019 | $244.59M(+155.3%) | $244.59M(+8.1%) |
| Jun 2019 | - | $226.23M(+12.4%) |
| Mar 2019 | - | $201.20M(+16.9%) |
| Dec 2018 | - | $172.06M(+79.6%) |
| Sep 2018 | $95.80M(+17.7%) | $95.80M(-6.4%) |
| Jun 2018 | - | $102.31M(-10.5%) |
| Mar 2018 | - | $114.27M(+61.5%) |
| Dec 2017 | - | $70.75M(-13.1%) |
| Sep 2017 | $81.42M(-14.8%) | $81.42M(-9.6%) |
| Jun 2017 | - | $90.10M(-4.0%) |
| Mar 2017 | - | $93.89M(-4.0%) |
| Dec 2016 | - | $97.76M(+2.3%) |
| Sep 2016 | $95.58M(-13.2%) | $95.58M(+59.4%) |
| Jun 2016 | - | $59.98M(-19.5%) |
| Mar 2016 | - | $74.48M(-19.8%) |
| Dec 2015 | - | $92.92M(-15.7%) |
| Sep 2015 | $110.18M(-33.8%) | $110.18M(-16.1%) |
| Jun 2015 | - | $131.30M(-9.3%) |
| Mar 2015 | - | $144.75M(-1.0%) |
| Dec 2014 | - | $146.26M(-12.2%) |
| Sep 2014 | $166.54M(+505.6%) | $166.54M(-10.6%) |
| Jun 2014 | - | $186.36M(-2.6%) |
| Mar 2014 | - | $191.40M(+131.3%) |
| Dec 2013 | - | $82.73M(+200.9%) |
| Sep 2013 | $27.50M(+149.3%) | $27.50M(-21.3%) |
| Jun 2013 | - | $34.96M(+558.0%) |
| Mar 2013 | - | $5.31M(-49.3%) |
| Dec 2012 | - | $10.47M(-5.0%) |
| Sep 2012 | $11.03M | $11.03M(+6.4%) |
| Jun 2012 | - | $10.37M(-30.4%) |
| Mar 2012 | - | $14.90M(-25.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | - | $20.07M(+46.6%) |
| Sep 2011 | $13.69M(+51.4%) | $13.69M(+28.8%) |
| Jun 2011 | - | $10.63M(-12.1%) |
| Mar 2011 | - | $12.09M(+50.1%) |
| Dec 2010 | - | $8.05M(-11.0%) |
| Sep 2010 | $9.05M(+86.2%) | $9.05M(-10.6%) |
| Jun 2010 | - | $10.11M(+72.1%) |
| Mar 2010 | - | $5.88M(-8.6%) |
| Dec 2009 | - | $6.43M(+32.3%) |
| Sep 2009 | $4.86M(-60.5%) | $4.86M(+15.3%) |
| Jun 2009 | - | $4.21M(+75.1%) |
| Mar 2009 | - | $2.41M(-65.6%) |
| Dec 2008 | - | $7.00M(-43.1%) |
| Sep 2008 | $12.30M(-53.2%) | $12.30M(-6.1%) |
| Jun 2008 | - | $13.10M(-31.3%) |
| Mar 2008 | - | $19.06M(-19.8%) |
| Dec 2007 | - | $23.77M(-9.6%) |
| Sep 2007 | $26.30M(-14.2%) | $26.30M(-20.7%) |
| Jun 2007 | - | $33.18M(+35.5%) |
| Mar 2007 | - | $24.48M(-18.8%) |
| Dec 2006 | - | $30.16M(-1.7%) |
| Sep 2006 | $30.67M(+17.4%) | $30.67M(-18.5%) |
| Jun 2006 | - | $37.62M(-8.7%) |
| Mar 2006 | - | $41.20M(+76.6%) |
| Dec 2005 | - | $23.33M(-10.7%) |
| Sep 2005 | $26.13M(+176.5%) | $26.13M(-8.2%) |
| Jun 2005 | - | $28.46M(+128.7%) |
| Mar 2005 | - | $12.44M(+51.3%) |
| Dec 2004 | - | $8.22M(-13.0%) |
| Sep 2004 | $9.45M(+565.5%) | $9.45M(-12.9%) |
| Jun 2004 | - | $10.85M(-5.4%) |
| Mar 2004 | - | $11.47M(+444.3%) |
| Dec 2003 | - | $2.11M(+48.4%) |
| Sep 2003 | $1.42M(+191.6%) | $1.42M(+180.9%) |
| Jun 2003 | - | -$1.75M(-3.2%) |
| Mar 2003 | - | -$1.70M(-6.6%) |
| Dec 2002 | - | -$1.60M(+13.8%) |
| Sep 2002 | -$1.55M(-18.9%) | -$1.85M(-26.2%) |
| Jun 2002 | - | -$1.47M(-6.4%) |
| Mar 2002 | - | -$1.38M(-0.7%) |
| Dec 2001 | - | -$1.37M(+14.8%) |
| Sep 2001 | -$1.30M(-15.5%) | -$1.60M(-29.0%) |
| Jun 2001 | - | -$1.24M(-2.7%) |
| Mar 2001 | - | -$1.21M(-4.4%) |
| Dec 2000 | - | -$1.16M(+27.6%) |
| Sep 2000 | -$1.13M(-13.4%) | -$1.60M(-37.6%) |
| Jun 2000 | - | -$1.16M(-5.2%) |
| Mar 2000 | - | -$1.11M(-5.0%) |
| Dec 1999 | - | -$1.05M(+28.2%) |
| Sep 1999 | -$996.10K(+62.1%) | -$1.47M(-55.8%) |
| Jun 1999 | - | -$942.50K(+63.4%) |
| Mar 1999 | - | -$2.57M |
| Sep 1998 | -$2.63M(-2.0%) | - |
| Sep 1997 | -$2.58M | - |
FAQ
- What is Arrowhead Pharmaceuticals, Inc. annual stockholders equity?
- What is the all-time high annual shareholders equity for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. annual shareholders equity year-on-year change?
- What is Arrowhead Pharmaceuticals, Inc. quarterly stockholders equity?
- What is the all-time high quarterly shareholders equity for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. quarterly shareholders equity year-on-year change?
What is Arrowhead Pharmaceuticals, Inc. annual stockholders equity?
The current annual shareholders equity of ARWR is $185.44M
What is the all-time high annual shareholders equity for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high annual stockholders equity is $461.78M
What is Arrowhead Pharmaceuticals, Inc. annual shareholders equity year-on-year change?
Over the past year, ARWR annual stockholders equity has changed by -$85.90M (-31.66%)
What is Arrowhead Pharmaceuticals, Inc. quarterly stockholders equity?
The current quarterly shareholders equity of ARWR is $522.31M
What is the all-time high quarterly shareholders equity for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high quarterly stockholders equity is $683.32M
What is Arrowhead Pharmaceuticals, Inc. quarterly shareholders equity year-on-year change?
Over the past year, ARWR quarterly stockholders equity has changed by +$191.77M (+58.01%)